马萨诸塞州萨福克县波士顿市中资背景药企Lynk 10月27日公布三期长期积极结果，类风湿新药疗效维持至76周
总部位于中国杭州、并在上海与波士顿设有业务的临床阶段创新药企业Lynk Pharmaceuticals于10月27日宣布，其在研选择性第二代口服JAK1抑制剂zemprocitinib治疗中重度活动性类风湿关节炎的关键三期临床试验取得积极长期结果。该试验针对的是对生物制剂改善病情抗风湿药反应不足或不耐受的成年患者，共随机入组430名患者，其中429人至少接受了一剂治疗；在最初24周双盲治疗期，患者接受每日两次12毫克zemprocitinib或安慰剂。试验达到了24周时ACR20应答率的主要终点及关键次要终点，与安慰剂相比有统计学显著改善；第52周与第76周的结果进一步显示，疾病活动度各项指标与身体功能持续改善，疗效维持至第76周。类风湿关节炎是一种慢性自身免疫性疾病，患者关节持续炎症可导致疼痛、功能受限乃至残疾，对现有生物制剂反应不足的患者群体尤其缺乏有效的口服治疗选择。该公司专注于免疫与炎症性疾病领域的创新药开发，波士顿是其美国业务的重要基地之一。此次公布的长期结果显示，该药的临床应答在长期治疗中维持至第76周。
Lynk Pharmaceuticals Reports Positive Long-Term Phase III Results on October 27 in Boston, Massachusetts, With Rheumatoid Arthritis Drug Efficacy Maintained Through Week 76
Lynk Pharmaceuticals, a clinical-stage innovative drug company headquartered in Hangzhou, China, with operations in Shanghai and Boston, announced on October 27 that its pivotal Phase III trial of zemprocitinib, an investigational selective second-generation oral JAK1 inhibitor, in moderate-to-severe active rheumatoid arthritis produced positive long-term results. The trial enrolled adult patients who had an inadequate response or intolerance to biologic disease-modifying antirheumatic drugs; 430 patients were randomized and 429 received at least one dose of treatment. During the initial 24-week double-blind period, patients received zemprocitinib 12 mg twice daily or placebo. The trial met its primary endpoint of ACR20 response and key secondary endpoints at Week 24, with statistically significant improvement over placebo; results at Week 52 and Week 76 further showed continued improvement in disease activity measures and physical function, with efficacy maintained through Week 76. Rheumatoid arthritis is a chronic autoimmune disease in which persistent joint inflammation can cause pain, functional limitation and disability, and patients who respond inadequately to existing biologics particularly lack effective oral treatment options. The company focuses on innovative drugs for immune and inflammatory diseases, and Boston is one of the key bases of its U.S. operations. The long-term results announced this time show that clinical responses to the drug were maintained through Week 76 of long-term treatment.
来源：GSM·美国（原文链接）
图片来源：资料图：波士顿市政厅（固定图库cities包），该公司波士顿业务所在地，图说注明资料图
